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48294 | RSC Adv., 2016, 6, 48294–483nano-based drug delivery systems
for eﬃcient delivery of phytochemicals in
chemotherapy
A. P. Subramanian,a S. K. Jaganathan,*a A. Manikandan,b K. N. Pandiaraj,c Gomathi Nd
and E. Supriyantoa
The advent of nanotechnology has revolutionized various scientiﬁc inventions, out of which the debut of
nanomedicine is outstanding. Especially, research has embarked on nano-drug delivery for treating
cancer. Natural compounds present in plants, namely phytochemicals, have been extensively exploited
for their anticancer properties. Despite their excellent anticancer abilities, phytochemicals are limited by
their low water solubility and poor bioavailability. However, the ﬁeld of nanotechnology has overcome
these limitations. This review focusses on various methods of nano-drug delivery of phytochemicals
against the killer disease, cancer. Common carriers that were employed ranged from micelles, with
a polymeric base, to dendrimers, liposomes and nanoparticles. The phytochemicals were found to
become more soluble when delivered by the nanocarriers and exhibited a remarkable eﬀect on the
cancer cells, compared to their free form. More interestingly, the half-maximal dose of the
phytochemical was reduced signiﬁcantly when it was delivered by the nanocarrier. On the whole, this
review encourages the idea of “cancer-nanotechnology” after in-depth clinical studies on these
phytochemical-loaded nanocarriers. Moreover, it will epitomize the nanocarriers as a crusader in
improving cancer chemotherapy by reducing undesired eﬀects and will invigorate site-speciﬁc drug
delivery.1. Introduction
Nature is able to help the technically evolving world with respect
to several newly arising diseases. Naturally available plant-
derived products have been used to prevent as well as treat
various diseases for many centuries by mankind.1 The curative
properties of these plant products are believed to be linked to
the natural compounds present in them. These compounds are
known as phytochemicals, or plant-derived chemicals. These
are chemical compounds produced by the plants that give color
or other organoleptic properties to them.2 Contemporary
researchers have shown that these natural compounds can
protect against many diseases.
Several population studies have shown that there are a few-
phytochemicals from fruits, vegetables and whole grains
that are active against cardiovascular disease, diabetes andtre, Faculty of Biosciences and Medical
, Johor Bahru 81310, Malaysia. E-mail:
58553; Tel: +60-7-5558548
ity, Chennai 600073, Tamil Nadu, India
ent of Physics, Sri Shakthi Institute of
ass, Chinniyam Palayam, Coimbatore-
te of Space Science and Technology,
14neurodegeneration. Apart from this, there is much literature
evidence to show the various health benets of phytochemicals
present in plants.3–5 Among these, the potential ability of
natural compounds against the killer disease, cancer, is
signicant. Regardless of these biological benets possessed by
the bioactive plant components, their usage in the medicinal
eld has a long way to go.6 Some of the factors that inuence
this are low water solubility, poor bioavailability and the
requirement for high doses. Furthermore, many investigations
have shown that these issues can be easily overcome by the
nano-based delivery of these phytochemicals. Nano-based
formulations have been found to improve solubility, bioavail-
ability, and specic targeting, while reducing the doses and
achieving steady-state therapeutic levels in cancer treatment.7
In general, all the biological processes that happen inside
the body, including the origin and prognosis of cancer, are said
to occur at the nano-level.8 Due to this, the application of
nanotechnology in the eld of medicine has ourished. Nano-
technology is one of the advanced multidisciplinary technolo-
gies that typically involves nano-level (109 m) investigation.9
Cancer is a major threat to mankind and is claimed to be the
second leading cause of death worldwide. According to a survey,
about 595 690 Americans are expected to die of cancer and
1 685 210 new cancer cases are expected to be diagnosed in the
US during the year 2016.10 The available treatments for cancerThis journal is © The Royal Society of Chemistry 2016
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View Article Onlinevary from chemotherapy to targeted radiotherapy. Regardless of
these diﬀerent treatment procedures, there is no single medical
procedure to treat cancer. Hence, the continuing threat of
cancer deaths motivates scientists to steadily concentrate on the
eld of oncology. One such more advanced mode of treatment
is cancer-nanotechnology, which combines nanomedicine and
cancer.11
The application of nanotechnology in the eld of oncology
oﬀers diﬀerent approaches to making signicant advances in
both cancer diagnosis and treatment. These renewed
approaches mainly deal with nanoparticles that are designed to
specically target and treat cancer by increasing the solubility
and bioavailability of encapsulated drugs.12 Although there is
a large number of studies to show the anticancer properties of
phytochemicals, this review mainly deals with the
nanotechnology-based drug delivery of several naturally avail-
able chemical compounds in the treatment of various types of
cancer. Before leading into this, a brief introduction to
chemotherapy is provided.2. Chemotherapy
Chemotherapy is a common choice of treatment adopted by
cancer patients around the globe. It mainly utilizes one or more
chemical substances known as anticancer drugs or chemo-
therapeutic drugs.13 These chemical substances are found to
have anti-cancer properties, along with the ability to destroy
cells that divide rapidly, one of the major properties of cancer
cells. This treatment is adopted before, aer or during other
types of treatment procedures, such as radiotherapy, surgery
and targeted radiotherapy.14 The eﬀectiveness of chemotherapy
is entirely dependent on the type as well as the stage of the
cancer. The eﬃcacy is fair and curative for cancers like
leukemia, while the treatment is unsuccessful in the case of
brain tumors or non-melanoma skin cancers. Nevertheless, the
eﬀectiveness of the treatment can be measured only aer 2 or 3
cycles of chemotherapy.15
Some of the commercially available chemotherapeutic drugs
include 5-uorouracil, doxorubicin, paclitaxel, oxaliplatin,
cisplatin, and epirubicin. All these chemotherapeutic drugs aﬀect
the cancer cells and induce apoptosis.16 Apoptosis is a pro-
grammed cell death in multicellular organisms involving a series
of biochemical changes as well as morphological changes, nally
leading to the death of the cell.17 A schematic representation of
the action of anti-cancer drugs on cancer cells is given in Fig. 1.
Chemotherapeutic drugs are generally consumed orally. However,Fig. 1 Outline of chemotherapy.
This journal is © The Royal Society of Chemistry 2016not all drugs can be orally administered and hence some are
injected subcutaneously, intra-muscularly or intravenously.
Anothermajor complexity of chemotherapy is the dosage at which
the chemotherapeutic drugs can be administered. The dose is
prescribed depending upon theweight and height of a person and
also based on the type of drug.18 This is mainly because, if the
dosage is low, then the treatment becomes ineﬀective, whereas if
the dosage is high, the chemotherapeutic drugs cause side eﬀects.
Adverse eﬀects or side-eﬀects of chemotherapy are a fore-
most concern of physicians and cancer patients around the
globe. A wide range of side-eﬀects are exhibited, depending on
the type of medication used. As chemotherapeutic drugs aﬀect
fast-growing cells, other growing cells, such as hair cells, blood
cells, bone marrow cells and the cells lining the mouth,
stomach, and intestines, are also aﬀected. Due to this, pregnant
women are advised to undergo abortion before chemotherapy.19
Besides this, chemotherapy leads to immunosuppression,
infertility, myelosuppression, gastrointestinal distress, typhli-
tis, anemia, fatigue, peripheral neuropathy, nausea and vomit-
ing.20 All these undesirable eﬀects of chemotherapeutic drugs
trigger research to search for a harmless substance with
signicant anticancer properties for cancer treatment. In
addition to new anticancer drugs, there is also much research
on administration methods that can individually target cancer
cells.
3. Phytochemicals
The word phyto means “plants” in Greek and phytochemicals
are naturally occurring plant-derived compounds. They are the
secondary metabolites or the bioactive compounds of plants.
These compounds are produced by plants as a protection
against diﬀerent environmental stresses, which include insects,
bacteria, fungi and weather changes.21 Nevertheless, the
occurrence of phytochemicals cannot be conned, as it is
spread throughout the range of ora and fauna found in nature.
A plant contains a variety of phytochemicals and the same
phytochemical is present in more than one plant.22 The chem-
ical formulae and the sources of the various phytochemicals
enlisted in this review are listed in Table 1. In the case of
eugenol, the main source is clove, while it is also found in
wormwood, cinnamon, vanilla, celery, and basil.23 Clove also
contains acetyl eugenol, beta-caryophyllene, vanillin, crategolic
acid, bicornin, gallotannic acid, methyl salicylate, eugenin,
kaempferol, rhamnetin, eugenitin, oleanolic acid, stigmasterol,
campesterol, and several sesquiterpenes.24 In order to maintain
a classication scheme, these plant-derived compounds have
been classied into groups and subgroups based on their
functional groups, structures and biosynthetic origins.25 A
summary of phytochemical classications is given in Fig. 2.
Phytochemicals are more abundant in the fruit and vege-
table extracts, chocolate, and tea, which are consumed in day-
to-day life. These compounds are usually described as non-
essential nutrients as they minimally contribute to the
growth, development and well-being of the individual. They
have long remained unnoticed by healthy eaters or dietitians
due to the fact that they are not required to sustain life.RSC Adv., 2016, 6, 48294–48314 | 48295
Table 1 Diﬀerent types of phytochemicals and their sources
Phytochemical Chemical structure Major source
Apigenin Parsley, celery, celeriac, chamomile tea
Berberine
Oregon grape, barberry, tree turmeric, goldenseal, yellow root, amur cork tree,
Chinese goldthread, prickly poppy, Californian poppy
Combretastatin A-4 Eastern Cape South African bush-willow tree, Brazilian mofumbo
Curcumin Turmeric
Ellagic acid
North American white oak, European red oak, medicinal mushroom
Phellinus linteus
Emodin Rhubarb, buckthorn, Japanese knotweed
Epigallocatechin gallate
White tea, green tea, black tea, apple skin, plums, onions, hazelnuts,
pecans and carob powder
48296 | RSC Adv., 2016, 6, 48294–48314 This journal is © The Royal Society of Chemistry 2016
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Table 1 (Contd. )
Phytochemical Chemical structure Major source
Ferulic acid Coﬀee, apple, artichoke, peanut, orange, female ginseng, axseed
Gallic acid
Indian gooseberry, gallnut, witch hazel, raspberry, North American white oak,
sundew, blackberry, hot chocolate, green tea
Gambogic acid Brownish or orange resin of Indian gamboge tree
Honokiol In the bark, seed cones, and leaves of trees belonging to the genus Magnolia
b-Lapachone In leaves and barks of Chinese catalpa
Luteolin
Ragweed pollen, celery, broccoli, green pepper, parsley, thyme, chamomile
tea, carrots, olive oil, peppermint, navel oranges
This journal is © The Royal Society of Chemistry 2016 RSC Adv., 2016, 6, 48294–48314 | 48297
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Table 1 (Contd. )
Phytochemical Chemical structure Major source
Noscapine In all plants of the poppy family
Nobiletin In the peels of citrus fruits
Resveratrol In the skin of grapes, blueberries, raspberries, mulberries
Silibinin Milk thistle seeds
Thymoquinone In the plant Nigella sativa and wild bergamot
Triptolide Thunder god vine
48298 | RSC Adv., 2016, 6, 48294–48314 This journal is © The Royal Society of Chemistry 2016
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Table 1 (Contd. )
Phytochemical Chemical structure Major source
Ursolic acid
Apples, basil, cranberries, elder ower, peppermint, rosemary, lavender,
oregano, thyme, hawthorn, prunes
Zerumbone Ginger
Fig. 2 Classiﬁcation of phytochemicals.
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View Article OnlineHowever, much research has been focused on these plant-
derived bioactive compounds and their biological benets.
Phytochemicals, when consumed along with the diet, have
proven eﬀective in ghting many chronic diseases, especially
cardiovascular disorders and cancer.26 Phytochemicals are
found to be a great source of antioxidants. Most phytochemicals
are found to excellently inhibit the proliferation of cells as well
as angiogenesis, the two main trademark characteristics of
cancer.27 Investigations of the anti-carcinogenic eﬀects of
phytochemicals under laboratory conditions and in various
animal models have been conducted. The results obtained
showed an improvement in the excretion of carcinogens, inhi-
bition of mitosis, subdual of inammatory processes, such as
cyclooxygenase-2 expression, and induction of apoptosis at
diﬀerent stages of cancer.28 Phytochemicals are proven to ghtThis journal is © The Royal Society of Chemistry 2016against various types of cancers, such as lung cancer, prostate
cancer, oral cancer, melanoma, leukemia, lymphoma, colon
cancer and breast cancer.29 Before embarking on various studies
related to the anticancer properties of phytochemicals, under-
standing their bioavailability is more important.4. Bioavailability of phytochemicals
Bioavailability is an important aspect of pharmacology.
Bioavailability literally means the amount or fraction of the
administrated drug that is absorbed into the systemic circula-
tion. The bioavailability of a drug depends upon the method of
administration and the receiving individual.30 Technically, the
bioavailability of a drug administered intravenously is one
hundred percent, while the bioavailability of drugs adminis-
tered non-intravenously is found to degenerate due to poor
absorption. In the case of other dietary supplements or
medicinal herbs, the bioavailability is much reduced when they
are consumed orally.31
The bioavailability of the phytochemicals present in the food
we consume is a critical factor that is extensively researched.
Manach et al. found that the bioavailability of dietary poly-
phenols is inuenced by the absorption in the gut, the micro-
biota metabolism, glucuronide excretion to the intestinal
lumen, plasma kinetics, liver and gut metabolism, accumula-
tion in tissues and bile, urinary excretion and a variety of
metabolites in the bloodstream, bonding to albumin, cell
assimilation and metabolism.32 The plasma concentrations of
the various phytochemicals were calculated to study their
complex bioavailability. For example, catechins are absorbed
rapidly and are supposed to be absorbed in the small intestine,
yet are aﬀected by dimerization. Compounds such asRSC Adv., 2016, 6, 48294–48314 | 48299
RSC Advances Review
Pu
bl
ish
ed
 o
n 
04
 M
ay
 2
01
6.
 D
ow
nl
oa
de
d 
on
 8
/1
2/
20
18
 5
:4
6:
11
 A
M
. 
View Article Onlineepigallocatechin gallate and other catechin monomers are
found to have similar properties. Meanwhile, the avanones are
slowly absorbed due to the attached disaccharides. The highest
bioavailability was seen in the isoavones subclass. In the case
of aglycones and glucosides, the absorption was relaxed, sug-
gesting absorption from the colon. Anthocyanins are quite
rapidly absorbed, but their bioavailability seems to be the
lowest of all avonoids.33 Similarly, proanthocyanidins and
hydroxycinnamic acids, which are abundant in the human diet,
were also not absorbed. The plasma concentrations of the iso-
avones were found to be 5 mmol L1, whilst the plasma
concentrations for proanthocyanidins did not exceed 1 mmol
L1. The bioavailability of phytochemicals is also inuenced by
the esterication process.34
For the most part, the phytochemicals present in plant foods
are poorly absorbed by human subjects, in which they are
rapidly metabolized and excreted. This is one of the major
issues to be faced before implementing these phytochemicals in
the war against cancer.
However, drug delivery involving nanocarriers has proven to
increase the bioavailability of these drugs. Manzoor et al.
studied the bioavailability of doxorubicin when delivered with
nano-liposomes. The bioavailability of doxorubicin was
improved by thermally sensitive liposomes released inside the
tumor vasculature. The maximum penetration of free doxoru-
bicin was previously limited to 34 mm, while this study depicted
a diﬀusion distance of about 78 mm in both sides of the capillary
bed of the tumor.35,36 Hence, the nano-drug delivery of phyto-
chemicals is thought to increase the possibility of anticancer
activity. The improved bioavailability during nanodrug delivery
is related to the route by which the phytochemicals from food
and the nanocarrier reach cancer cells. This is shown dia-
grammatically in Fig. 3. The anticancer eﬀects of the nano-drug
delivery of phytochemicals against various types of cancer is
discussed in further chapters.
A particular study was carried out to overcome this limitation
by Manzoor et al. The bioavailability of doxorubicin was
improved by the release of thermally sensitive liposomes inside
the tumor vasculature. The maximum penetration of doxoru-
bicin was previously limited to 34 mm, while this study depicted
a diﬀusion distance of about 78 mm in both sides of the capillaryFig. 3 Common routes of phytochemical administration from food
and nano-carriers.
48300 | RSC Adv., 2016, 6, 48294–48314bed of the tumor.25,26 Therefore, the nano-drug delivery of the
phytochemicals is thought to increase the possibility of anti-
cancer activity. The anticancer eﬀect of the nano-drug delivery
of phytochemicals against various types of cancer is discussed
in further chapters.5. Nano-drug delivery of
phytochemicals against cancer
Despite the advanced treatment choices available for cancer
patients, there is no particular method to cure cancer
completely. This motivates scientists to continue their research
on anticancer drugs and an eﬀective way of administration. In
addition to this, there is an enormous group of phytochemicals
that have been proven to exhibit anticancer eﬀects against
diﬀerent types of cancer. To enhance their minor backlogs,
scientists employ the recently developed technique nanotech-
nology. This is a technology that manipulates matter with at
least one dimension at the nanometer scale. The comprehen-
sive nature of nanotechnology has allowed its application in
a number of scientic elds, including organic chemistry,
surface science, semiconductor physics, molecular biology,
microfabrication, medicine, and biotechnology. In almost all
cases, these applications involve the use of nanomaterials.37 In
particular, nanomaterials are used to build nano-systems that
vary in size from 1–100 nm and are employed as transport
modules to carry another substance or drug in nanomedicine.
Such a nano-system may also be called a nanocarrier.38 There
are diﬀerent kinds of nanocarriers that are used to deliver drugs
to treat deadly diseases, such as cancer. The role of nanocarriers
in cancer is inevitable as it plays a major part in both visuali-
zation and therapy. This is due to the fact that these nano-
carriers can be easily fabricated to selectively target cancer cells
from normal cells.39 Some of the main nanocarriers used in
cancer are micelles, liposomes, dendrimers, carbon nanotubes,
nanoshells and nanocages. The major principles involved in the
manufacturing of some nanocarriers are diagrammatically
depicted in Fig. 4. As shown in the diagram, a micelle is an
aggregate of molecules with an outer hydrophobic head region
and a hydrophilic tail region in the micelle centre. A dendrimerFig. 4 Phytochemicals loaded to diﬀerent types of nanocarriers.
This journal is © The Royal Society of Chemistry 2016
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View Article Onlineis a highly branched, star-shaped macromolecule with
nanometer-scale dimensions that is symmetric around the
core.40,41 Liposomes are similar to micelles; they are spherical
vesicles in which hydrophilic and hydrophobic groups are
arranged to form a lipid bilayer. A nanocomposite consists of
multiphase materials with at least one of them being in a nano-
dimension.42,43
All these nanocarriers allow the delivery of hydrophobic and
hydrophilic drugs throughout the body. As most of the human
body contains water, this ability of the nanocarrier contributes
to the therapeutic eﬃciency, while another is the targeted
delivery of the drug.44 The drugs carried are harmful to the
normal cells present in the human body. The nanocarriers
carefully deliver the drugs to the specic site due to their site-
specicity and smaller size. The four types of targeting charac-
teristics of nanocarriers are passive, active, pH-sensitive and
temperature-sensitive. The nanocarrier targets the delivery
based on pH and temperature changes in cancer cells, and it
may also be cloaked to match the circulation time by coating
materials such as PEG. In the case of active targeting, the
nanocarrier is provided with a cell-specic ligand.45 The fore-
most application of these nanocarriers is focused on cancer
chemotherapy. This may be because of the lower pH, the higher
temperature, the hydrophobic nature of the anticancer drugs
and the potential need for specic targeting ability.46 Another
major advantage of nanocarriers in cancer is the enhanced
permeability and retention (EPR) eﬀect. This involves the
aggregation of macromolecules or nanoparticles in the extrav-
asation in the tumor tissue during angiogenesis or the forma-
tion of new blood vessels. All the above factors make the
application of nanotechnology in cancer benecial.47 However,
the major literature on the nano-drug delivery of various
phytochemicals against major cancers is enumerated in the
following subdivisions.Fig. 5 Formation of polymeric micelles.5.1 Lung cancer
Lung cancer is also known as pulmonary carcinoma, and is
characterized by uncontrolled cell growth in the lungs. It is one
of the most common causes of cancer-related death in men and
women. The major types of lung cancer include small-cell lung
carcinoma, non-small-cell lung carcinoma and lung carcinoid
tumor.10,48 The small-molecule, polyphenol honokiol, was found
to have a therapeutic eﬀect against lung cancer. The honokiol
was loaded to micelles based on poly(3-caprolactone)–poly-
(ethylene glycol)–poly(3-caprolactone) copolymer (PCEC). The
size of the obtained honokiol-loaded PCEC micelles was about
61 nm. However, the particle size decreased in correspondence
to an increase in temperature, making it more suitable for drug
delivery when injected via blood. Both the free honokiol and
honokiol-loaded micelles had a dose-dependent anti-
proliferative eﬀect on A549 human lung adenocarcinoma cells
and were comparable. The prepared micelles showed a typical
two-phase-release prole under in vitro conditions.49 Merlin
et al. studied the anticancer eﬀect of phenolic phytonutrient
ferulic-acid-loaded poly-D,L-lactide-co-glycolide (PLGA) nano-
particles on non-small-cell lung carcinoma cell lines. TheThis journal is © The Royal Society of Chemistry 2016ferulic-acid-loaded PLGA nanoparticles were prepared by
a double emulsion method and had a particle size of about 483
nm. The NCI-H460 cells were treated with ferulic acid alone as
well as with the ferulic-acid-loaded PLGA nanoparticles. The
results depicted an increased anticancer eﬀect by the ferulic-
acid-loaded nanoparticles. Furthermore, the nanoparticle-
induced cytotoxicity involved an increase in the level of reac-
tive oxygen species (ROS), DNA damage, altered mitochondrial
transmembrane potential (MMP) and apoptotic morphological
changes. These factors suggest that ferulic-acid-loaded PLGA
nanoparticles are a suitable therapeutic tool against lung
cancer.50
The novel anticancer drug, b-lapachone (b-lap), which is
bioactivated by NAD(P)H:quinone oxidoreductase-1 (NQO1), an
enzyme found specically overexpressed in non-small-cell lung
cancer (NSCLC), was delivered using nanoparticles. The b-lap
was incorporated into poly(ethylene glycol)-co-poly(D,L-lactic
acid) (PEG–PLA) polymer micelles using a lm sonication
procedure. The prepared micelles had core–shell architecture
and were about 30 nm in size. The b-lap micelles were injected
via the tail vein or caudal vein of mice with subcutaneous A549
lung tumors and the biodistribution was studied. The results
showed a prolonged blood circulation and increased accumu-
lation of b-lap. In addition, the in vitro administration of the
micelles to LLC tumors led to DNA damage and PARP-1
hyperactivation.51 The basic principal involved in the forma-
tion of polymeric micelles is illustrated in Fig. 5. Zhang et al.
examined the combinational eﬀect of b-lapachone and pacli-
taxel micelles against A549 non-small-cell lung cancer (NSCLC)
cells. The co-encapsulation of b-lapachone and paclitaxel in the
PEG–PLA micelles had an encapsulation eﬃciency of 100.7 
2.2% and a drug-loading eﬃciency of about 100.3  3.0%. The
combinational b-lapachone and paclitaxel micelle was found to
have an improved eﬀect compared to the b-lapachone micelle
and paclitaxel micelle alone. The combinational micelle had
a signicant antiproliferative eﬀect at an IC50 of 0.16 mM, while
the individual IC50 s were 4.5 mM and 0.32 mM for the b-lapa-
chone micelle and the paclitaxel micelle, respectively. Thus, the
two compounds were supposed to exhibit a synergistic eﬀect
against lung cancer.52
The avonoid, luteolin, was encapsulated into a nanocarrier
and tested against H292 lung cancer cells. The nanocarrier had
a polymeric base, made up of polylactic acid and polyethylene
glycol (PLA–PEG). The nanoparticle formed had a mean size ofRSC Adv., 2016, 6, 48294–48314 | 48301
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View Article Onlineabout 115 nm. The luteolin-loaded nanoparticle and free
luteolin both showed antiproliferative activity against H292
cells. The IC50 of nano-luteolin was signicantly less than that
of free luteolin, showing that the nanosystem contributes to
improved bioavailability. Similar results were observed in
a colony formation assay.535.2 Breast cancer
Breast cancer is a malignant tumor that starts in the cells of the
breast and occurs commonly in women. Women around the age
of 40 to 70 years are more prone to breast cancer. It ranks as the
second most common cause of death worldwide and, if le
untreated, easily spreads to other parts of the body. The
metastasis of breast cancer is found to cause lung cancer in
many cases.10,48 The diarylheptanoid compound, curcumin, was
delivered using a biologically derived nanoparticle to MCF-7
and MDA-MB-453 breast cancer cell lines and its therapeutic
eﬀects were recorded. The nanoparticle was manufactured from
covalently blended silk broin and chitosan (SFCS) polymers or
silk brin polymer alone by the capillary-microdot technique.
All the synthesized nanoparticles were less than 100 nm in size
and were tested with breast cancer cell lines. Interestingly, the
silk broin showed a higher uptake and eﬃcacy than SFCS
nanoparticles in both breast cancer cell lines. The cell viability
of both the breast cancer cell lines was decreased more by the
silk broin nanoparticles than by the SFCS nanoparticles.54
Sebak et al. produced a nanoparticle from human serum
albumin (HSA) for the targeted delivery of noscapine and
enumerated its response with SK-BR-3 breast cancer cells.
Noscapine is obtained from plants of the poppy family and is
a benzylisoquinoline alkaloid. The pH-coacervation method
was employed to form HAS nanoparticles and noscapine-loaded
nanoparticles. The nanoparticle size ranged from 150–300 nm
and had 85–96% drug-loading eﬃciency. About 10% of nosca-
pine was released with the initial burst from the nanoparticle
followed by a sustained drug release. The SK-BR-3 breast cancer
cells were treated with the HAS nanoparticles as well as with the
noscapine-loaded HAS nanoparticles. Both the drug-loaded and
drug-free nanoparticles reduced the viability of the breast
cancer cells, whilst the eﬀect of noscapine-loaded nanoparticles
was signicantly higher.55
A pH-sensitive liposome was used to deliver ursolic acid,
a triterpenoid compound, to MDA-MB-231 breast cancer cells.
The pH-sensitive liposomes were prepared by the lipid hydra-
tionmethod. The liposomes had amean diameter of 191.1 6.4
nm and long-term stability. The liposomes were predominantly
of a vesicle size less than 100 nm, promising good drug-loading
eﬃciency. The MDA-MB cells were exposed to the pH-sensitive
ursolic acid liposomes. The IC50 value of the ursolic acid lipo-
somes was much lower than that of the free ursolic acid, indi-
cating the improved anticancer activity of the nano-liposomes.56
Odeh et al. prepared two diﬀerent kinds of liposomes,
thymoquinone-loaded liposomes (TQ-LP) and thymoquinone
loaded in liposomes modied with Triton X-100 (XLP). Thy-
moquinone is an herbal-derived phytochemical that has excel-
lent chemopreventive properties and is hydrophobic in nature.48302 | RSC Adv., 2016, 6, 48294–48314Both the nanoparticles had a diameter of about 100 nm, while
the entrapment eﬃciency was more than 90% for TQ-LP and
49.6% for XLP. Their biological activity was studied using both
MCF-7 cancer cells and broblast cells. However, the TQ-LP
eﬀectively suppressed the proliferation of MCF-7 cells and
exerted very low toxicity on normal periodontal ligament
broblasts.57
The inhibitory eﬀect of silibinin and D-a-tocopheryl poly-
ethylene glycol 1000 succinate (TPGS) on breast cancer cells was
recorded. Silibinin-loaded lipid nanoparticles containing TPGS
and phosphatidylcholine were designed and prepared by a thin-
lm hydration method. The nanoparticles had an average size
of 45 nm and the encapsulation eﬃciency of silibinin in the
nanoparticle was 98.63  0.30%. Cellular uptake studies
showed that the drug content in MDA-MB-231 breast cancer
cells aer silibinin nanoparticle treatment for 24 h was about
twice as much as that aer free silibinin treatment. Corre-
sponding results were observed for cell viability, invasion and
migration assays. However, the silibinin-loaded nanoparticles
strongly suppressed the invasive and migratory capabilities of
MDA-MB-231 cells at a concentration of 20 mg mL1 through the
downregulation of the MMP-9 and Snail pathways. Thus, it was
concluded that the silibinin-loaded TPGS nanoparticles could
be used as a novel therapeutic agent against breast cancer.58
Sharma et al. used dendrimers to deliver the phenolic phyto-
chemical, gallic acid, for inhibiting breast cancer cells. The
dendrimers were made up of polyamidoamine (PAMAM) using
Tomalia's divergent growth approach. The dendrimers provided
a high degree of surface functionality and versatility for the
gallic acid loaded onto them. The cytotoxicity of the gallic-acid-
loaded PAMAM nanoparticles was found using MCF-7 human
breast cancer cells. The MCF-7 cells were treated with the
PAMAM dendrimer, gallic acid and the gallic-acid-loaded
PAMAM nanoparticles. The IC50 values showed that the gallic-
acid-loaded PAMAM nanoparticles had a synergistic anti-
proliferative eﬀect on the growth of MCF-7 cells.595.3 Colorectal cancer
Cancer that occurs in the colon or rectum is termed as colo-
rectal cancer. It ranks as the third most common type of cancer,
as the American Cancer Society estimates 136 830 new cases
and 50 310 deaths due to colorectal cancer in the United States
for 2016. It is more susceptible to the foods we consume as the
colonic epithelial cells come into direct contact with them.10,48
Zheng et al. recorded the cytotoxicity of triptolide and triptolide-
loaded polymeric micelles against HT-29 human adenocarci-
noma cells. Triptolide is a diterpenoid tri-epoxide puried from
the Chinese herb, Tripterygium wilfordii, which has anticancer
properties but exhibits some other side eﬀects. The triptolide-
loaded polymeric micelles (TP-PM) were synthesized using
methoxypoly(ethylene glycol)–poly lactic acid (MePEG–PLA)
copolymer by a solvent evaporation method. Both the free
triptolide and the TP-PM had a dose- and time-dependent eﬀect
on the HT-29 cells; however the inhibitory eﬀects of TP-PM on
the tumor cell growth were more signicant for all incubation
times and concentrations. In addition to this, the incubation ofThis journal is © The Royal Society of Chemistry 2016
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View Article OnlineHT-29 cells with triptolide and the TP-PM also resulted in an
increase in the caspase 3/7 activity, indicating apoptosis, with
the highest apoptosis index at 6.96 aer 48 h incubation with 10
ng mL1 TP-PM. Hence, the polymeric micelles served as an
excellent carrier of TP and reduced its toxicity.60 The small-
molecule polyphenol compound, honokiol, was loaded into
the self-assembled biodegradable star-shaped micelles and
tested for chemotherapeutic eﬀects. The biodegradable poly-
meric micelles were made up of monomethoxy poly(ethylene
glycol) (MPEG) and poly(3-caprolactone) (PCL) and loaded with
the honokiol by a direct dissolution method assisted by ultra-
sonication. The average particle size of the obtained honokiol
micelles was about 40 nm and these were used to treat CT26
murine colon carcinoma cells. The release rate of honokiol from
the star-shaped polymeric micelles was slower. Nevertheless,
they exhibited an antiproliferative eﬀect against the CT26 cells
in a dose-dependent fashion. Therefore, this star-shaped hon-
okiol micelle may be used to design a new dosage form.61
Ravindran et al. studied the anti-proliferative properties of
the bioactive phytochemical, Nigella sativa thymoquinone,
loaded in poly(lactide-co-glycolide) (TQ-PLGA) nanoparticles
using human colon cancer HCT116. The TQ-PLGA nano-
particles had an encapsulation eﬃciency around 94% and
ranged between 150 and 200 nm in size. The TQ-PLGA nano-
particles had an eﬀective anticancer eﬀect against the HCT116
cells. Apart from this, the nanoparticles were active in inhibit-
ing NF-kB activation and in suppressing the expression of cyclin
D1, matrix metalloproteinase (MMP)-9, and vascular endothe-
lial growth factor (VEGF) when compared to the free thymo-
quinone. On the whole, the results demonstrate that
encapsulation of TQ into nanoparticles enhances its anti-
proliferative eﬀects.62 Luteolin (Lu), is a avonoid with anti-
cancer activity but it is said to have poor water solubility. This
was delivered by monomethoxy poly(ethylene glycol)–poly(3-
caprolactone) (MPEG–PCL) micelles under in vivo conditions to
evaluate the biodistribution and to C-26 colon carcinoma cells
to determine their anticancer properties. The MPEG–PCL
micelles encapsulated Lu by a self-assembly method. Fabricated
Lu/MPEG–PCLmicelles were water-soluble with an approximate
size of about 38.6 nm and an encapsulation eﬃciency of about
98.32%. The pharmacokinetics of free luteolin and Lu/MPEG–
PCL micelles was studied in rats, suggesting that the bioavail-
able concentration of luteolin was more when the Lu/MPEG–
PCL micelles were used. Furthermore, the Lu/MPEG–PCL
micelles inhibited the growth of C-26 colon carcinoma cells at
an IC50 of 12.62 2.17 mg mL1. Hence, the study indicates that
encapsulation of Lu into MPEG–PCL micelles created an
aqueous formulation of Lu with a potential anticancer eﬀect.63
Zhang et al. enlisted the eﬀects of self-carried curcumin
nanoparticles for in vitro and in vivo colon cancer therapy. The
curcumin nanoparticles were prepared by the re-precipitation
method and were then anchored to poly(maleic anhydride-alt-
1-octadecene)–polyethylene glycol (C18PMH–PEG) on the
surface by ultrasonication to improve the biocompatibility of
the nanoparticles. The nanoparticles had a loading eﬃciency of
about 78.5%, an encapsulation eﬃciency of about 95.8% and
displayed sustained release behaviour without any initial burst.This journal is © The Royal Society of Chemistry 2016The curcumin nanoparticles were tested for their anticancer
properties with CT-26 colon cancer cells. The results showed
that the curcumin nanoparticles produced an 8-fold decrease in
the half-maximal inhibitory concentration (IC50) values of the
free curcumin (IC50 ¼ 33.4 mM) compared to the curcumin
nanoparticles (IC50 ¼ 4.2 mM). Analogous results were seen in
the in vivo testing. Aer administration of the curcumin and
curcumin nanoparticles to CT-26 tumor-bearing nude mice, the
tumor volumes were 87% and 32%, respectively. This shows
that the curcumin nanoparticle has a greater eﬀect than free
curcumin on the tumor cells. However, the curcumin nano-
particles had no adverse eﬀects or toxicity when investigated for
in vivo systemic toxicity.645.4 Skin cancer
Skin cancer is the most common form of cancer, globally
accounting for at least 40% of cases, and it is especially
common among people with light skin. The most dangerous
type of cancer occurs in the melanoma or the cells that contain
melanocyte pigments. Exposure to the ultraviolet radiation
emitted by the sun is said to be a major cause of cancer.10,48 Das
et al. extensively studied the eﬀects of the avone, apigenin,
against melanoma when delivered using poly(lactic-co-glyco-
lide) nanoparticles. These were prepared by the solvent
displacement method. The prepared nanoparticles demon-
strated a biphasic release prole, showing an initial burst fol-
lowed by controlled release for 3 days. The anti-proliferative
eﬀect of the nanoparticles was examined with A375 skin mela-
noma and HaCaT keratinocytes. It was observed that the
nanoparticle had a dose-dependent eﬀect on the A375 cells,
with an IC50 of 15 mM, where the apigenin alone had an IC50 of
25 mM. In contrast, there was no cytotoxic eﬀect on the normal
HaCaT cells. The nanoparticles induced the intercalation of
double-stranded DNA (dsDNA), along with an increase in ROS
accumulation and a reduction in the antioxidant enzyme
activities, mediating apoptosis through mitochondrial
dysfunction.65 This was followed by a study on the anti-
carcinogenic eﬀect of apigenin-loaded poly(lactic-co-glycolide)
nanoparticles against ultra-violet B (UVB) and benzo(a)pyrene
(BaP)-induced skin tumor in mice. Along with the anti-
carcinogenic eﬀect, changes in the mitochondria were also
studied aer apigenin delivery. The apigenin-loaded nano-
particles showed better results against UVB–BaP-induced
melanoma, which may be related to their smaller size and
faster mobility. The nanoparticles decreased the tissue damage
as well as the frequency of chromosomal aberrations. Apart
from this, there was an increase in the ROS generation, mito-
chondrial matrix swelling and modulation of the apoptotic
markers, such as Apaf-1, bax, bcl-2 and cyt c. Thus, the apigenin-
loaded poly(lactic-co-glycolide) nanoparticles possess potential
ability for therapeutic management of skin cancer.66
In yet another study, the dihydrostilbenoid, combretastatin
A-4 was co-encapsulated with doxorubicin and tested for anti-
cancer properties under both in vitro and in vivo conditions. The
compounds were loaded onto the RGD-modied liposomes.
The cellular uptake of doxorubicin by the integrin-RSC Adv., 2016, 6, 48294–48314 | 48303
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View Article Onlineoverexpressing B16 and B16F10 melanoma cells was improved
by the disrupting agent, combretastatin A-4. Moreover, the co-
encapsulated liposomes were more toxic towards the mela-
noma cells than the doxorubicin-loaded liposomes. Similarly,
the combretastatin A-4 and doxorubicin-loaded liposomes
exhibited the most pronounced tumor regression eﬀect in male
C57BL/6 mice inoculated with melanoma B16F10 cells. Thus,
the combretastatin A-4 encapsulation improved the eﬃcacy of
the doxorubicin.67 Siddiqui et al. recently studied the anti-
proliferative and pro-apoptotic eﬀects of epigallocatechin 3-
gallate (EGCG) encapsulated in chitosan nanoparticles on
human melanoma cell growth, under both in vitro and in vivo
conditions. The EGCG was loaded onto nanoparticles made up
of polylactic acid–polyethylene glycol in order to enhance its
bioavailability to the melanoma cells. The Mel 928 cells were
used to test the eﬀects of EGCG-loaded nanoparticles and free
EGCG. The results showed that there was about an 8-fold dose
advantage of this nano-formulation over native EGCG in
retarding the growth of melanoma cells. Furthermore, a growth
of Mel 928 tumor xenogra in the mice model was observed
when EGCG-loaded nanoparticles were given. This inhibition
included cell cycle phase arrest and changes in the level of
cyclins D1 and D3 protein expression.685.5 Ovarian cancer
Ovarian cancer occurs when there is an uncontrolled growth of
cells in the ovary. Women who have ovulated more over their
lifetime and those who have never had children are more
vulnerable to ovarian cancer. According to the statistical
reports, about 14 240 women will die from ovarian cancer in the
US alone and death from ovarian cancer is more common in
North America and Europe than in Africa and Asia.10,48 The
small-molecule polyphenol, honokiol, was loaded onto a nano-
particle and was delivered to ovarian cancer cells under labo-
ratory conditions. The nanocarrier was manufactured with
monomethoxy poly(ethylene glycol)–poly(lactic acid) (MPEG–
PLA) by the ring opening polymerization method and then
honokiol was loaded onto it by a solvent extraction method. The
honokiol-loaded MPEG–PLA nanoparticles had a spherical
appearance with a mean particle size of ca. 80 nm. The nano-
particles were found to release 53% of the drug within 24 h
under laboratory conditions. Both the free honokiol and
honokiol-loaded MPEG–PLA decreased the viability of A2780
human ovarian cancer cells with increasing concentration.
However, the honokiol-loaded MPEG–PLA nanoparticles
potentially inhibited the growth of A2780 cells at an IC50 was
8.45 mg mL1. This was greater than the eﬀect of the free hon-
okiol.69 Yallapu et al. studied the improved therapeutic eﬀects of
curcumin loaded to poly(lactic-co-glycolide) (PLGA) nano-
particles and its anti-cancer eﬀect against cisplatin-resistant
A2780CP ovarian cancer cells. The fabricated nanoparticles
were found have an average size of 560.4 nm and exhibited
a sustained and controlled drug release of curcumin under in
vitro conditions. The curcumin-loaded PLGA nanoparticles
inhibited the growth of the A2780CP cells at an IC50 of about
13.9 mM, which was superior when compared to the eﬀects of48304 | RSC Adv., 2016, 6, 48294–48314free curcumin. Similar results were seen in the examination of
long-term eﬀects and the curcumin-loaded PLGA nanoparticles
reduced the number of cancer cells in the colony. These results
suggest that the curcumin-loaded PLGA nanoparticles are an
ideal therapeutic agent.70
The anticancer activity and molecular mechanism of
resveratrol-bovine serum albumin nanoparticles (RES-BSANP)
on subcutaneously implanted human primary ovarian carci-
noma cells in nude mice was examined in recent years. A tumor
was induced by injecting SKOV ovarian cancer cells into the
nude mice, which were given 200, 100, and 50 mg kg1 RES-
BSANP or 0.5 mL RES once a week. Observation of the tumor
progression showed that the RES-BSANP signicantly retarded
the growth of carcinomas in nude mice from the third week
onwards, and the inhibition rate was markedly higher than in
mice treated with RES. The RES-BSNAP was found to induce
apoptosis by releasing cytochrome c and regulating caspase-3, 9,
thereby indicating a mitochondrial apoptotic pathway.71 The
hydrophobic drug, curcumin, was encapsulated into a hydro-
philic polymeric core and delivered to the SKOV-3 ovarian
cancer cells. The hydrophilic polymeric core was made up of
poly(2-hydroxyethyl methacrylate) [PHEMA] nanoparticles. Aer
loading the curcumin, the nanoparticles had a size of about 300
nm. In vitro investigations showed that the curcumin-loaded
nanoparticles showed better tumor cell regression activity
than free curcumin. Furthermore, they also showed a notable
decrease in the G0/G1 phase cells. These nanosystems that
delivered curcumin showed excellent biocompatibility when
studied with a zebrash embryo model.725.6 Prostate cancer
The malignant growth of cells in the prostate gland of the male
reproductive organ leads to prostate cancer. As the cancer
develops in the glands, it is medically termed as adenocarci-
noma. According to the American Cancer Society, about 180 890
new cases of prostate cancer are expected in 2016, which means
that 1 in 7 American men will be diagnosed with prostate
cancer.10,48 The gallic acid ester derivative, epigallocatechin 3-
gallate (EGCG) was delivered to prostate cancer cells by
a biodegradable nanoparticle. Here, EGCG was combined with
polylactic acid–polyethylene glycol polymeric proles along
with prostate-specic membrane antigen (PSMA)-targeting
ligands. The pseudomimetic dipeptide, N-[N-[(S)-1,3-dicarbox-
ypropyl]carbamoyl]-(S)-lysine (DCL) was the PSMA-targeting
ligand. An anti-proliferative eﬀect was exhibited by the tar-
geted nanoparticles as well as the non-targeted nanoparticles
on LNCaP androgen-sensitive human prostate adenocarcinoma
cells. Both the nanoparticles were exposed to PCa prostate
cancer cells. The growth inhibition exhibited by EGCG-loaded
nanoparticles showed high eﬃcacy and target specicity.
Apart from this, the EGCG-loaded nanoparticles were found to
be ineﬀective in inhibiting HUVEC proliferation. Thus the
developed nanoparticles were proven to exhibit selective toxicity
against prostate cancer.73 Zu et al. evaluated the enhanced tar-
geting ability of folate-mediated EGCG bovine serum albumin
nanoparticles (FA-EGCG-BSANP) against PC-3 prostate cancerThis journal is © The Royal Society of Chemistry 2016
Fig. 6 Extraction and loading of curcumin.
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View Article Onlinecells. The nanoparticles were prepared by the desolvation
method and possessed a mean particle size of about 200 nm
with an entrapment eﬃciency of about 81.5%. The folate-
mediated nanoparticles were found to exhibit concentration-
dependent targeting to the PC-3 cells. The PC-3 cells' uptake
of FA-EGCG-BSANP was 23.65 times that of the EGCG-BSANP.
The folate present in the nanoparticles was found to improve
the lethality toward PC-3 cells due to FA-EGCG-BSANP.74
In yet another experiment, the gallate, EGCG, was delivered to
prostate cancer cells using a nanocarrier and its results were
recorded. The nanocarrier was made up of polylactic acid–poly-
ethylene glycol (PLA–PEG) and was tested under in vivo as well as
in vitro conditions. The eﬀect of nano-trapped EGCG was 10-fold
higher than that of free EGCG against PCa prostate cancer cells.
The IC50 was measured to be 3.74 mmol L
1 for the EGCG-loaded
nanoparticles and there was a signicant increase in pro-
apoptotic Bax with a concomitant decrease in anti-apoptotic
Bcl-2 in the PCa cells. The 22Rn1 cells were injected into the
mice, which were then given EGCG-loaded nanoparticles as well
as free EGCG. The outcome was similar to that under in vitro
conditions and the tumor size was reduced signicantly.75
Besides the gallate, the yellow polyphenol, curcumin, was
also explored for its anticancer properties. Mukerjee et al.
developed a curcumin-loaded nanoparticle and investigated its
anticancer properties against the prostate cancer cell lines,
LNCaP, PC3 and DU-145. Curcumin was loaded to poly(lactic-co-
glycolic acid) (PLGA) nanospheres prepared by a solid/oil/water
emulsion solvent evaporation method. The prepared nano-
spheres were found to have a mean size of about 45 nm with
a biphasic drug release manner. The curcumin-loaded PLGA
nanospheres were found to be more eﬀective than the free cur-
cumin. This was reected in the half-maximal inhibitory value.
The IC50 of curcumin-loaded PLGA nanospheres ranged from 20
mM–22.5 mM, while that of free curcumin ranged from 32 mM to
34 mM. Besides this, the curcumin-loaded PLGA nanospheres
also strongly inhibited the NF-kB function when compared to
free curcumin.76 In yet another study, the anticancer eﬀect of
nanoemulsion containing both curcumin and resveratrol was
done. Separate nanoemulsions containing liposomes loaded
with curcumin and liposomes loaded with resveratrol were
prepared and co-administered to the PTEN-CaP8 cancer cells
and the PTEN knockout mice with prostate cancer. In vitro
studies showed that the curcumin with resveratrol eﬀectively
inhibited cell growth and induced apoptosis. In addition to this,
the combination also signicantly repressed the expressions of
p-Akt, AR, cyclin D1 and mTOR proteins in PTENCap8 cells with
loss of PTEN. Similarly, the mice that were given the combina-
tion (25 mg kg1) had a more positive response than the mice
administered with either lipo-curcumin or lipo-resveratrol (50
mg kg1 each) for 7 weeks. A notable reduction in the prostate
weight in the combination treatment group conrmed the
decrease in the incidence of mouse prostatic intraepithelial
neoplasia (mPIN) lesions. Apart from these, the availability of
curcumin was improved during the co-administration of lipo-
curcumin and lipo-resveratrol.77 A diagrammatic representa-
tion of extraction as well as loading of curcumin is given in
Fig. 6.This journal is © The Royal Society of Chemistry 20165.7 Cervical cancer
Cervical cancer is a cancer arising from the cervix, a part of the
uterus. In 90% of cases, cervical cancer is found to occur due to
human papillomavirus (HPV) infection. It ranks as the fourth
most common cause of death from cancer in women, globally.
However, cervical pre-cancers are diagnosed far more oen than
invasive cervical cancer.10,48 A uorescence study of the curcu-
min–casein micelle complex and its application as a drug
nanocarrier to cancer cells was done by Sahu et al. The curcu-
min was loaded to bovine casein micelles and the prepared
micelles were less than 200 nm with a roughly spherical shape.
These curcumin-micelles were formed due to hydrophobic
interactions between the casein micelles and curcumin. HeLa
cervical cancer cells were used to study the cellular uptake and
toxicity of free curcumin and curcumin–casein micelles. The
green uorescence emitted aer the treatment showed that the
casein micelles had improved the uptake of the curcumin. The
cellular uptake showed a concentration-dependent increase.
Similar results were obtained from cytotoxicity studies and the
IC50 of free curcumin and the CM-curcumin complex was 14.85
and 12.69 mM, respectively. This showed that the casein
micelles proved to be a good drug carrier.78 Das et al. loaded the
yellow phytochemical, curcumin, to alginate–chitosan–pluronic
composite nanoparticles to deliver it to HeLa cancer cells. The
nanocomposite particles were created with the alginate, chito-
san and pluronic using ionotropic pre-gelation and polycationic
cross-linking. The pluronic was used to improve the solubility of
curcumin, which was veried in the encapsulation eﬃciency
studies. The nanoparticles had an average size of about 100 nm.
The drug release from the nanoparticle occurred in a controlled
manner and the cellular uptake was acceptable in the HeLa
cells. Apart from this, the cell viability of HeLa cells was
signicantly decreased by the curcumin-loaded composite
nanoparticles at a concentration of 500 mg mL1.795.8 Liver cancer
Liver cancer, oen referred as hepatic cancer, is a cancer that
originates in the liver. It is usually diagnosed accidentally and
mostly occurs due to cirrhosis, which is due to due to either
hepatitis B, hepatitis C, or alcohol. About 39 230 new cases are
expected to be diagnosed by the American Cancer Society in
2016.10,48 Lin et al. investigated the eﬀect of berberine, a form of
isoquinoline alkaloid, in the liposomal form against hepatoma.
The berberine liposome was manufactured by the thin-lm
hydration/extrusion method and contained 5% mol polyethyleneRSC Adv., 2016, 6, 48294–48314 | 48305
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View Article Onlineglycol (PEG). The berberine liposomes had an encapsulation
eﬃciency of 14% and were exposed to HepG2 liver hepatocellular
carcinoma cells. The berberine liposomes exhibited 2.5 times
more toxicity against the HepG2 cells than the berberine solution.
The berberine liposome signicantly inhibited the growth of
HepG2 cells at 1.67 mg berberine per mL and induced apoptosis
through the caspase/mitochondria-dependent pathway. Further-
more, the liposome was tested under in vivo conditions in nude
mice bearing the HepG2 tumor. The results showed that the
berberine liposomes eﬀectively reduced the size and weight of
tumors, causing a reduction in the rate of elimination of berberine
in both plasma and tissues. Therefore, the work demonstrated
that the liposome was a good carrier for the berberine.80 On the
other hand, the same phytochemical was delivered as a nano-
suspension to the human hepatocytes, HepG2 and Huh7 cells.
The nanosuspension consisted of the berberine phytochemical
and D-a-tocopheryl polyethylene glycol 1000 succinate (TPGS) with
an average size of 73.1  3.7 nm. The nanosuspension had
a signicant eﬀect on the growth of HepG2 and Huh7 cells at
concentrations of 8.1 and 4.7 mg mL1. In contrast, the free
berberine suppressed the growth of the hepatoma cells at 18.3 and
6.5 mg mL1 (HepG2 and Huh7 cells, respectively). In the in vivo
experiment with H22 solid tumor-bearing mice, the berberine
nanosuspensions had an inhibition rate of 63.7%, while the free
berberine had an inhibition rate of only 41.4%. Thus, the nano-
suspension has improved the availability of the phytochemical to
the cancer cells.81
Studies to were done record the eﬀect of a xanthonoid,
gambogic acid, loaded in lactoferrine nanoparticles, against
cancer. Lactoferrine is a cationic iron-binding glycoprotein and
gambogic acid-lactoferrin nanoparticles (GL-NPs) were
produced by nanoparticle albumin-bound (NAB) technology.
The GL-NPs had a mean size of about 150 nm and an encap-
sulation eﬃciency of 7.2%, and the in situ intestinal perfusion
displayed a good absorption of the gambogic acid from the GL-
NPs. The GL-NPs showed almost an identical antiproliferative
eﬀect in the HepG2 liver carcinoma cells to that of the arginine
solution of gambogic acid. Apart from this, the GL-NPs exhibi-
ted a high inhibitory rate when orally administered to S180
tumor mice and controlled the tumor growth. This was about
1.39-fold higher than the eﬀect of an arginine solution of
gambogic acid. These studies have also paved a preliminary way
for the study of lactoferrine as an oral drug delivery carrier.82
Zhai et al. prepared apigenin-loaded polymeric micelles and
tested their antiproliferative eﬀect against HepG2 liver carci-
noma cells. The polymeric micelles were composed of Pluronic
P123 and Solutol HS 15 with an average diameter of 16.9 nm.
They had an entrapment eﬃciency and drug loading of 96.36%
and 1.32%, respectively. Around 84% of the apigenin was
delivered by the polymeric micelles, displaying a sustained
drug-release behaviour. The IC50 values on HepG2 cells for
apigenin-loaded polymeric micelles and free apigenin solution
were 5.57 mg mL1 and 20.19 mg mL1, respectively. The growth
of HepG2 cells was signicantly reduced by the apigenin
micelles at lower concentrations than the free apigenin, which
may be related to its improved hydrophilic characteristics.8348306 | RSC Adv., 2016, 6, 48294–48314The diarylheptanoid compound, curcumin, was conjugated
to gum arabic and was used against hepatoma cell lines. Gum
arabic is a polysaccharide substance, which is used to improve
the solubility of curcumin. The self-assembled conjugates had
a spherical structure and a mean size of 270 nm. When tested,
the formed curcumin conjugate had improved the solubility
and stability of curcumin at physiological pH. Apart from this,
the curcumin conjugation retarded the growth of the HepG2
hepatocellular carcinoma cells. They also exhibited a higher
targeting ability toward the cells due to the galactose groups
present in gum arabic.84 Beside the berberine nanosuspensions,
resveratrol nanosuspensions were also prepared recently. The
resveratrol nanosuspension contained resveratrol and polox-
amer 188 and was manufactured using a high-pressure
homogenization technique. The average size of the nano-
suspension was 159 nm and it was evaluated for its eﬀect on
HepG2 cells, along with free resveratrol. The results of an MTT
assay showed that the resveratrol inhibited the proliferation of
HepG2 cells at an IC50 of 2.91 mg mL
1. In contrast, the free
resveratrol had a similar eﬀect only at 7.13 mg mL1. Hence,
these results suggest that the delivery of the resveratrol nano-
suspension is a promising approach for treating tumors.855.9 Pancreatic cancer
Pancreatic cancer arises in cells in the pancreas, a glandular
organ behind the stomach; therefore, it is mostly termed as
pancreatic adenocarcinoma. It ranks as the seventh most
common cause of death with about 40 560 deaths predicted in
2016 alone. It is usually due to usage of tobacco and obesity.10,48
The polyphenol, curcumin, was explored for its anticancer
properties against pancreatic cancer. Nanocurcumin or
curcumin-encapsulated nanoparticles were synthesized using
micellar aggregates of cross-linked and random copolymers of
N-isopropylacrylamide (NIPAAM), with N-vinyl-2-pyrrolidone
(VP) and poly(ethylene glycol)monoacrylate (PEG-A). The
developed nanocurcumin was found to readily disperse in an
aqueous medium, displaying its hydrophilic nature. The Mia-
Paca pancreatic cancer cell line was treated with curcumin and
nanocurcumin. Both of these signicantly suppressed the
growth of pancreatic cancer cells at 10 and 15 mM, respectively.
Furthermore, the nanocurcumin obstructed the activation of
nuclear factor kappa B (NFkB) and downregulated the IL-6, IL-8,
and TNFa cytokines, thereby inducing cellular apoptosis. Thus,
it was found that the nanocurcumin possessed all the properties
of curcumin with better solubility.86 Wei et al. entrapped the
phytochemical, curcumin, as an ester to cholesteryl-hyaluronic
acid (CHA) nanogel and employed this in a targeted delivery to
CD44-expressing drug-resistant MiaPaca cancer cells. The
curcumin-conjugated nanoparticle was 20 nm in diameter with
a spherical structure. Gastrointestinal stability studies showed
that the curcumin-loaded nanoparticles were absorbed in the
gastrointestinal tract and then entered the blood circulation.
Thus, it was concluded that the oral administration of the
nanoparticles with curcumin would lead to 2–5% loss. Apart
from this, the nanoparticle induced apoptosis in cancer cells,
suppressing the expression of NF-kB, TNF-a, and COX-2 cellularThis journal is © The Royal Society of Chemistry 2016
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View Article Onlinetargets in a similar way to free curcumin. Moreover, the
curcumin-loaded nanoparticles suppressed the tumor growth
by up to 13-fold in a 4T1 mice model injected with the MiaPaca
cells. Hence, the nano-drug delivery of curcumin is found to be
an ideal therapy for cancer.87
Kesharwani et al. produced parenterally administrable nano-
micelles of 3,4-diuorobenzylidene curcumin (CDF) for treating
pancreatic cancer. The 3,4-diuorobenzylidene curcumin is
a non-toxic analogue to the curcumin known for its high anti-
cancer activity, and it showed improved pancreas-specic
accumulation in vivo, compared with curcumin. The nano-
micelles were prepared by self-assembling the styrene–maleic
acid copolymer (SMA) with CDF, using non-covalent hydro-
phobic interactions. These were found to have a sustained drug
release behaviour when exposed to MiaPaCa-2 and AsPC-1
pancreatic cancer cell lines. The free CDF and the SMA–CDF
nanomicelles showed toxicity against both the cell lines and the
eﬀect of the nano-micelles was superior to that of the free CDF.
The IC50 was calculated as 230  4.68 nM for MiaPaCa-2 cells
and 710  3.81 nM for AsPC-1 cells.88 In addition to this, the
same research group evaluated the response of CDF loaded to
hyaluronic acid-conjugated polyamidoamine dendrimers given
to CD44-overexpressing MiaPaCa-2 pancreatic cancer cells. The
nanocarrier was made of poly(amidoamine) (PAMAM) and
hyaluronic acid (HA) as a targeting ligand and then loaded with
the CDF (HA–PAMAM–CDF). The whole dendrimer system had
a particle size of 9.3  1.5 nm. These displayed a dose-
dependent cytotoxicity against MiaPaCa-2 and AsPC-1 human
pancreatic cancer cells. The half-maximal value was found to
have a 1.71-fold increase in the presence of the HA-ligand.
However, the developed nanocarrier was found to be an excel-
lent therapeutic device against CD44-overexpressing pancreatic
cancer.895.10 Oral cancer
Any cancerous growth witnessed in the oral cavity is generally
termed as oral cancer. Usually, it arises as a primary lesion in
any of the tissues in the mouth, which gradually spreads. Oral
cancer is twice as common in men as in women and the
American Cancer Society estimated 9450 deaths due to this in
2016.10,48 Dihydroartemisinin (DHA), the active metabolite of
artemisinin, was loaded onto a co-polymeric micelle and
delivered to oral cancer cells under laboratory conditions. The
co-polymeric micelles were made up of methoxy poly(ethylene
glycol)/poly(L-lactic acid) (mPEG) and loaded with the DHA
using a modied solvent evaporation method. Physicochemical
observations revealed that the nanoparticles were stable,
spherical in shape and had a mean size of about 130 nm. The
release of DHA from the co-polymeric micelles was pH-
dependent and exhibited biphasic drug release behaviour,
with an initial burst followed by a slightly faster drug release. An
MTT assay showed that the DHA delivered from the micelle had
a superior anticancer eﬀect on KB human oral cancer cells as
the IC50 was found to be 18.70 mM, while that for the free DHA
was 24.55 mM. This showed that the nano-drug delivery
improved the availability of the drug delivered. Besides, theThis journal is © The Royal Society of Chemistry 2016DHA-micelle-treated cells showed some physical signs of
apoptosis.90 In recent years, the polyphenolic compound, ellagic
acid, was encapsulated in chitosan nanoparticles and delivered
to the KB human oral cancer cell line. The ellagic acid was
entrapped in the chitosan nanoparticles using the ionic gela-
tion method. The nanoparticles were found to have a spherical
shape and an average size of about 176 nm. Furthermore, the
drug encapsulation eﬃciency was around 94%, while the
loading eﬃciency was 33%, and the nanoparticle was found to
exhibit sustained drug release behaviour. The ellagic acid was
found to have a better therapeutic competence against the KB
cells when delivered using the chitosan nanoparticles. They
exhibited a dose-dependent eﬀect and had an IC50 value of
0.953 mg mL1, along with visible DNA fragmentation in the KB
cells.915.11 Leukemia
Leukemia is the name given to a group of cancers that usually
begin in the bone marrow and result in high numbers of
abnormal white blood cells. It is common among children in
developed countries and about 24 450 deaths were estimated by
the American Cancer Society.10,48 Anand et al. investigated the
antiproliferative activity of curcumin-loaded PLGA nano-
particles under laboratory conditions as well as the improved
bioavailability of this method by in vivo examination. The cur-
cumin drug was loaded to a polymer-based nanoparticle made
up of poly(lactide-co-glycolide) (PLGA) and a stabilizer, poly-
ethylene glycol (PEG), with 97.5% encapsulation eﬃciency.
KBM-5 human chronic myeloid leukemia cells were then
exposed to the curcumin-loaded PLGA–PEG. It was found that
the curcumin-loaded nanoparticles showed an improved
cellular uptake, inhibition of TNF-induced NF-kB activation,
suppression of NF-kB-regulated proteins involved in cell
proliferation (cyclin D1), invasion (MMP-9), angiogenesis
(VEGF) and induced apoptosis compared to free curcumin. In
the case of the mice, 2.5 mg kg1 of curcumin nanoparticles
were injected intravenously. HPLC analysis showed that the
curcumin nanoparticles were more bioavailable and had
a longer half-life than free curcumin.92 In another study, a co-
formulation of doxorubicin and curcumin in poly-(D,L-lactide-
co-glycolide) nanoparticles suppressed the development of
multidrug resistance in K562 chronic myeloid leukemia cells.
The doxorubicin and curcumin-loaded PLGA nanoparticles
were prepared by the single emulsion solvent evaporation
technique with an encapsulation eﬃciency of 46% and 86%,
respectively. When used to treat K562 cells, the cellular uptake
of dual drug-loaded NPs was nearly 8 times higher than the dual
drug in solution. Apart from this, the nanoparticles exhibited
signicant growth inhibition at an IC50 value of 0.1 mg mL
1
when the nanoparticles were administered in equivalent
concentrations, along with a gradual decrease in the expres-
sions of MDR1 and BCL-2 at the mRNA level. Overall, this
combinational strategy has more noteworthy promise than that
of the drugs alone.93
Wang et al. studied the antileukemia mechanism of the
multifunctional Chinese traditional medicine, emodin, whenRSC Adv., 2016, 6, 48294–48314 | 48307
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View Article Onlineconjugated to D-a-tocopheryl polyethylene glycol 1000 succinate
(TPGS) to form liposomes. The liposomes had a high encapsu-
lation eﬃciency of about 95.2%  3.0% and had a particle size
of 121.1  44.9 nm. The emodin-TPGS liposomes were found to
have an increased cytotoxicity toward L1210 and K562 leukemia
cell lines. This cytotoxicity included the regulation of protein
levels of myeloid cell leukemia 1 (Mcl-1), B-cell lymphoma-2
(Bcl-2) and Bcl-2-associated X (Bax). A bio-distribution study
showed that the emodin-TPGS liposomes improved the
bioavailability of emodin by 1.7 times compared to the free
emodin in lungs and kidney.94 The antiproliferative activity of
citrus polymethoxylated avone nobiletin-loaded chitosan
nanoparticles was recorded in parallel. The nobiletin-loaded
chitosan nanoparticles were formed via Schiﬀ-base formation
and had a loading eﬃcacy of 7.0%. An in vitro experiment was
carried out using RAW264.7 Abelson murine leukemia virus-
induced tumor cell lines and L-929 normal subcutaneous
connective tissue at various time intervals. It was found that
both the raw nobiletin as well as the nobiletin-loaded chitosan
nanoparticles suppressed the growth of RAW264.7 cells, while
they did not aﬀect the growth of L-929. Moreover, the nobiletin-
loaded chitosan nanoparticles showed considerable inhibition
at an IC50 of 8 mg mL
1 toward cancerous cells, revealing their
great potential for applications in cancer chemotherapy.95
Rahman et al. studied the antileukemic eﬀect of a natural
dietary lipophilic compound when loaded to nanostructured
lipid carriers. The zerumbone-loaded nanostructured lipid
carriers were formed by a high-pressure homogenization tech-
nique. The obtained ZER-NLC particles had an average size of
52.68  0.1 nm and a drug-loading eﬃciency of about 7.92%.
The drug release of zerumbone from ZER-NLC was about 46.7%
over 48 hours. When used to treat Jurkat acute lymphoblastic
leukemia cells, the ZER-NLC signicantly inhibited their growth
with an IC50 of 5.64  0.38 mg mL1. Thus, the study suggests
the ZER-NLC is a suitable sustained-release drug carrier system
for the treatment of leukemia.96Fig. 7 Eﬀect of phytochemicals against cancer cells.
Fig. 8 Molecular targets of phytochemicals loaded inside nanocarriers
against cancer cells.5.12 Cancer in the nervous system
The occurrence of cancer in the nervous system is a very rare
scenario and aﬀects the nervous system; examples are brain
cancer and sarcomas of the nerves.48 The growth inhibition
eﬀect of resveratrol when delivered by a biodegradable nano-
particle was studied by Shao et al. A biodegradable nanoparticle
was made up of mPEG–PCL and the resulting nanoparticle has
a smooth spherical shape. The drug-loading eﬃciency was about
19%, while the encapsulation eﬃciency was 91% for the mPEG–
PCL nanoparticles. These were tested against C6 glioma cells. A
glioma is a tumor that starts from the brain or spine and from
the glial cells. The resveratrol-loaded nanoparticles exhibited
greater cytotoxicity than the free resveratrol. Furthermore, the
amount of ROS generated by the C6 cells when exposed to the
resveratrol-loaded nanoparticles was comparatively more.
Hence, this study suggests that Res-loaded nanoparticles could
be a potential chemotherapeutic formulation for malignant
glioma therapy.97 The curcumin phytochemical, which has the
capacity to inhibit beta amyloid, is investigated for its ability to48308 | RSC Adv., 2016, 6, 48294–48314retard the growth of SH-SY5Y neuroblastoma cells. Neuroblas-
toma is an extracranial solid cancer growth composed of neu-
roblasts, most commonly in the adrenal gland. The curcumin
was loaded to apolipoprotein E3-mediated poly(butyl) cyanoac-
rylate nanoparticles, which had a particle size of around 195 nm.
Moreover, cell viability studies showed an enhanced therapeutic
eﬀect on neuroblastoma cells with a sustained drug-release
eﬀect. Similar to the anticancer activity of curcumin, the devel-
oped nanoparticles induced ROS generation and sub-G1 cell
cycle phase arrest along with induction of caspase-3. Hence, they
concluded that the curcumin-loaded nanoparticles induced
apoptosis in SH-SY5Y cells.985.13 Other cancers
Sou et al. studied the cytotoxicity of self-organized assemblies of
curcumin micelles against myeloma cells. Myeloma is a malig-
nant tumor that occurs in the bone marrow cells, known as
plasma cells. The lipophilic drug, curcumin, was loaded to the
amphiphatic poly(oxyethylene) cholesteryl ether (PEG-Chol) to
form micelles. The curcumin-loaded PEG-Chol nanoparticles
possessed more cytotoxicity against the myeloma cells. The
viability of the myeloma cells was signicantly decreased by the
curcumin-loaded PEG-Chol nanoparticles at 1 mM, while the
free curcumin had a signicant eﬀect at 5 mM. Hence, the PEG-This journal is © The Royal Society of Chemistry 2016
Table 2 Summary of phytochemicals and their nanocarriers employed against various cancers
Type of cancer Cell line tested Phytochemical Nanocarrier Reference
Lung A549 human lung
adenocarcinomic cells
Honokiol Poly(3-caprolactone)-
poly(ethylene glycol)–poly(3-
caprolactone) copolymer
micelle
49
NCI-H460 non-small-cell
lung carcinoma cells
Ferulic acid Poly-D,L-lactide-co-glycolide
(PLGA) nanoparticles
50
A549 human lung
adenocarcinomic cells
b-Lapachone Poly(ethylene glycol)-co-
poly(D,L-lactic acid) (PEG–
PLA) polymer micelles
51
A549 human lung
adenocarcinomic cells
b-Lapachone and paclitaxel Poly(ethylene glycol)-co-
poly(D,L-lactic acid) (PEG–
PLA) polymer micelles
52
H292 lung cancer cells Luteolin Polylactic acid and
polyethylene glycol (PLA–
PEG) nanoparticles
53
Breast MCF-7 human breast
adenocarcinoma cell line
and MDA-MB-453
Curcumin Silk broin and chitosan
(SFCS) polymer
nanoparticles
54
SK-BR-3 human breast
cancer cells
Noscapine Human serum albumin
(HSA) nanoparticles
55
MDA-MB-231 breast cancer
cells
Ursolic acid pH-sensitive liposomes 56
MCF-7 human breast
adenocarcinoma cell line
Thymoquinone Liposomes modied with
Triton X-100 (XLP)
57
MDA-MB-231 breast cancer
cells
Silibinin Lipid nanoparticles
containing D-a-tocopheryl
polyethylene glycol 1000
succinate (TPGS) and
phosphatidylcholine
58
MCF-7 human breast
adenocarcinoma cell line
Gallic acid PAMAM dendrimers 59
Colorectal HT-29 human
adenocarcinoma cells
Triptolide MePEG–PLA copolymer
micelles
60
CT26 murine colon
carcinoma cells
Honokiol Monomethoxy poly(ethylene
glycol) (MPEG) and poly(3-
caprolactone) (PCL) star-
shaped micelles
61
HCT-116 human colon
cancer cells
Thymoquinone Poly(lactide-co-glycolide)
(PLGA) nanoparticles
62
C-26 colon carcinoma cells Luteolin Monomethoxy poly(ethylene
glycol)–poly(3-caprolactone)
(MPEG–PCL) micelles
63
CT-26 colon cancer cells Curcumin Curcumin nanoparticles
anchored with C18PMH–PEG
on the surface
64
Melanoma A375 skin melanoma and
HaCaT keratinocytes
Apigenin Poly(lactic-co-glycolide)
nanoparticles
65 and 66
B16 and B16F10 melanoma
cells
Combretastatin A-4 and
doxorubicin
RGD (arginylglycylaspartic
acid)-modied liposomes
67
Mel 928 melanoma cells Epigallocatechin 3-gallate
(EGCG)
Polylactic acid–polyethylene
glycol nanoparticles
68
Ovarian A2780 human ovarian cancer
cells
Honokiol Monomethoxy poly(ethylene
glycol)–poly(lactic acid)
(MPEG–PLA) nanocarrier
69
A2780CP ovarian cancer cells Curcumin Poly(lactic-co-glycolide)
(PLGA) nanoparticles
70
SKOV ovarian cancer cells Resveratrol Bovine serum albumin
nanoparticles
71
SKOV-3 ovarian cancer cells Curcumin Poly(2-hydroxyethyl
methacrylate) [PHEMA]
nanoparticles
72
This journal is © The Royal Society of Chemistry 2016 RSC Adv., 2016, 6, 48294–48314 | 48309
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Table 2 (Contd. )
Type of cancer Cell line tested Phytochemical Nanocarrier Reference
Prostate LNCaP human prostate
adenocarcinoma cells and
PCa prostate cancer cells
Epigallocatechin 3-gallate
(EGCG)
Polylactic acid–polyethylene
glycol prostate-specic
membrane antigen (PSMA)
ligands
73
PC-3 human prostate cancer
cells
Bovine serum albumin
nanoparticles
74
PCa prostate cancer cells Polylactic acid–polyethylene
glycol (PLA–PEG)
nanocarrier
75
LNCaP human prostate
adenocarcinoma cells, PC3
human prostate cancer cells
and DU-145 PC3 human
prostate cancer cells
Curcumin Poly(lactic-co-glycolic acid)
(PLGA) nanospheres
76
PTEN-CaP8 Mouse prostate
epithelium cancer cells
Curcumin and resveratrol Curcumin and resveratrol
nanoemulsions
77
Cervical HeLa cervical cancer cells Curcumin Bovine casein micelles 78
Alginate–chitosan–pluronic
composite nanoparticles
79
Hepatoma HepG2 hepatocellular
carcinoma cells
Berberine Berberine polyethylene
glycol (PEG) liposome
80
Berberine Berberine and D-a-
tocopheryl polyethylene
glycol 1000 succinate (TPGS)
nanosuspension
81
Gambogic acid Lactoferrine nanoparticles 82
Apigenin Pluronic P123 and solutol
HS 15 polymeric micelles
83
Curcumin Gum arabic nanoparticles 84
Resveratrol Resveratrol and poloxamer
188 nanosuspension
85
Pancreatic MiaPaca pancreatic cancer
cell line
Curcumin N-Isopropylacrylamide
(NIPAAM), with N-vinyl-2-
pyrrolidone (VP) and
poly(ethylene glycol)
monoacrylate (PEG-A)
86
Cholesteryl-hyaluronic acid
(CHA) nanogel
87
Diuorobenzylidene
curcumin (CDF)
Styrene–maleic acid
copolymer (SMA) micelles
88
Poly(amidoamine) (PAMAM)
and hyaluronic acid
nanocarrier
89
Oral KB human oral cancer cells Dihydroartemisinin Methoxy poly(ethylene
glycol)/poly(L-lactic acid)
(mPEG) micelles
90
Ellagic acid Chitosan nanoparticles 91
Leukemia KBM-5 myeloid leukemia
cells
Curcumin Poly(lactide-co-glycolide)
(PLGA) and polyethylene
glycol (PEG) nanoparticles
92
K562 myeloid leukemia cells Doxorubicin and curcumin Poly-(D,L-lactide-co-glycolide)
nanoparticles
93
L1210 mouse lymphocytic
leukemia cells and K562
myeloid leukemia cells
Emodin D-a-Tocopheryl polyethylene
glycol 1000 succinate (TPGS)
liposomes
94
RAW264.7 abelson murine
leukemia virus-induced
tumor cell lines
Nobiletin Chitosan nanoparticles 95
Jurkat acute lymphoblastic
leukemia cells
Zerumbone Nanostructured lipid
carriers
96
Glioma C6 glioma cells Resveratrol mPEG–PCL nanoparticles 97
48310 | RSC Adv., 2016, 6, 48294–48314 This journal is © The Royal Society of Chemistry 2016
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Table 2 (Contd. )
Type of cancer Cell line tested Phytochemical Nanocarrier Reference
Neuroblastoma SH-SY5Y neuroblastoma Curcumin Apolipoprotein E3 mediated
poly(butyl) cyanoacrylate
nanoparticles
98
Myeloma Myeloma cells Curcumin Poly(oxyethylene) cholesteryl
ether (PEG-Chol) micelles
99
Gastric SGC7901 gastric cancer cells Ursolic acid Methoxy poly(ethylene
glycol)–polycaprolactone
(mPEG–PCL) nanocarrier
100
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cumin.99 The hydrophobic ursolic acid is able to induce cell
death when delivered to SGC7901 gastric cancer cells using
nanoparticles. Gastric cancer develops from the cells present in
the inner lining of the stomach and generally aﬀects older
people. Ursolic acid nanoparticles were prepared using methoxy
poly(ethylene glycol)–polycaprolactone (mPEG–PCL) block
copolymers as drug carriers by the nano-precipitation method.
The produced nanoparticles are nearly spherical, have an
average size of 144 nm and around 80% encapsulation eﬃ-
ciency. It was found that the free ursolic acid and ursolic acid-
loaded nanoparticles had an eﬀect on SGC7901 cells, whereas
the nanocarrier alone did not produce any toxic eﬀect. More-
over, the ursolic-acid-loaded nanoparticles had a stronger eﬀect
and elicited more cell death. Cell death involved the inhibition
of COX-2 and activation of caspase-3. Therefore, the study oﬀers
an eﬀective way to improve the anticancer eﬃciency of UA
through a nano-drug delivery system.1006. Conclusion
Nature has provided us with a vast variety of things and has
become part of man's life. It has not only given us food to eat,
water to drink, and fresh air to breath, but it has also provided
some other supports that can save our lives. Phytochemicals are
one such wonderful gi that helps to cure some threatening
diseases. These phytochemicals have been continuously
exploited by scientists for their medicinal properties, such as
antibiotic, antioxidant, antifungal, and antiviral. One of the
most prominent properties is the anticancer eﬀect of these
phytochemicals, as cancer is claimed to be the second leading
cause of death worldwide.10 A sustained search for a novel
anticancer drug and a better method of administration has
always existed. In this scenario, the advanced eld of nano-
technology has elevated cancer therapy to a new level.
The nano-drug delivery of anticancer agents has interested
many researchers in recent years. This is primarily due to their
reliable and targeted delivery, increased drug eﬃciency, and
improved cellular interaction, along with less toxicity to the
surroundings. These advantages are the same for synthetic
anticancer drugs and phytochemicals with an anticancer eﬀect.
Fascinatingly, the response elicited by the phytochemicals
delivered using nanocarriers is similar to that of the same
phytochemical in the free form. However, the half-maximalThis journal is © The Royal Society of Chemistry 2016inhibitory concentration of the drug is reduced to a greater
extent when nanotechnology is employed (Fig. 7). These natural
compounds are found to suppress the growth of cancer cells by
inducing programmed cell death, which is indicated by notable
changes, such as DNA damage,49 increased ROS generation,49,65
release of cytochrome C,71,98 activation of caspases 3/7,60,71,100 cell
cycle arrest,72 activation of NF-kB86,92 and downregulation of
MMP, BaX, cyclin D and VEGF,62,92,94 along with visible
morphological apoptotic changes.50 The diﬀerent targets of
phytochemicals loaded inside nanocarriers are given in Fig. 8.
The review summarized the nano-drug delivery of more than
een phytochemicals against various types of cancer. Among
them, the yellow diarylheptanoid compound, curcumin, has
been exploited against almost all types of cancer enlisted in the
review. Phytochemicals such as apigenin, resveratrol, honokiol
and epigallocatechin gallate (EGCG) are other commonly tested
compounds. The phytochemicals are found to become more
hydrophilic in nature when attached to a nanocarrier. From our
studies, it is found that the most regularly preferred nanocarrier
is a micelle with a polymeric base. A micelle is a nanostructure
that has both a hydrophobic part and a hydrophilic part. The
common polymeric bases employed for the micelles are poly-
(ethylene glycol) (PEG), polylactic-acid (PLA), poly-lactide-co-
glycolide (PLGA), and methoxy poly(ethylene glycol) (mPEG),
which are known for their good biocompatibility and biode-
gradable behaviour. Apart from the nano-micelles, dendrimers,
liposomes, nanocomposites and nanoparticles act as nano-
carriers for delivering drugs. The various phytochemical and
their nanocarriers along with the cell line tested is given in
Table 2.
The nano-drug delivery of phytochemicals has been exten-
sively investigated in a large number of cell studies and a few
animal studies. Preclinical testing with normal mice, nudemice
and knockout mice bearing cancer cells has shown suppression
of tumor growth. Besides these positive aspects, there is a lack
of studies that deal with the toxicity and other adverse eﬀects
that are produced by the nanocarriers. Hence, more in-depth
studies relating to the genotoxicity of the nanocarriers and
other possible side eﬀects should be initiated. Moreover, the
phytochemicals are known to exhibit a synergistic eﬀect against
cancer cells. They have the ability to increase a particular
property when used in combination. Previous studies have
shown that phytochemicals when combined have improved
cytotoxicity towards cancer cells.101 It would be interesting toRSC Adv., 2016, 6, 48294–48314 | 48311
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View Article Onlineinvestigate the outcome of these combinations with nano-drug
delivery for cancer. In addition to this, clinical studies on nano-
drug delivery as well as the mode of administration should be
carried out to promote them in the eld of medical oncology.
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